Substance P induces expression of the corticotropin-releasing factor receptor 1 by activation of the neurokinin-1 receptor

Brain Research

Volumn 1102, Issue 1, 2006, Pages 135-144

  Hamke, Maike ^a   Herpfer, Inga ^a   Lieb, Klaus ^a   Wandelt, Carolin ^a   Fiebich, Bernd L ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Affective disorder; Depression; Etiology; HPA axis; Signal transduction; Somatostatin receptor type 4; Therapy

Indexed keywords

3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; PROTEIN KINASE C; SUBSTANCE P;

ANIMAL CELL; ARTICLE; ASTROCYTOMA CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA MICROARRAY; EXPERIMENTAL MODEL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MACROGLIA; MOOD DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; ASTROCYTOMA; BLOTTING, WESTERN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PIPERIDINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECEPTORS, NEUROKININ-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBSTANCE P; TIME FACTORS;

EID: 33746190642     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.03.026     Document Type: Article

References (62)

1. Axelrod J., and Reisine T.D. Stress hormones: their interaction and regulation. Science 224 (1984) 452-459
2. Azzolina A., Guarneri P., and Lampiasi N. Involvement of p38 and JNK MAPKs pathways in substance P-induced production of TNF-alpha by peritoneal mast cells. Cytokine 18 (2002) 72-80
3. Banki C.M., Bissette G., Arato M., O'Connor L., and Nemeroff C.B. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am. J. Psychiatry 144 (1987) 873-877
4. Beaujouan J.C., DaguetdeMontety M.C., Torrens Y., Saffroy M., Dietl M., and Glowinski J. Marked regional heterogeneity of 125I-Bolton Hunter substance P binding and substance P-induced activation of phospholipase C in astrocyte cultures from the embryonic or newborn rat. J. Neurochem. 54 (1990) 669-675
5. Beaujouan J.C., Teutsch B., Saffroy M., Petitet F., Torrens Y., and Glowinski J. NK-1 receptors are the only class of tachykinin receptors found on mouse cortical astrocytes. Peptides 12 (1991) 813-820
6. Bondy B., Baghai T.C., Minov C., Schule C., Schwarz M.J., Zwanzger P., Rupprecht R., and Moller H.J. Substance P serum levels are increased in major depression: preliminary results. Biol. Psychiatry 53 (2003) 538-542
7. Brar B.K., Chen A., Perrin M.H., and Vale W. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. Endocrinology 145 (2004) 1718-1729
8. Chen R., Lewis K.A., Perrin M.H., and Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 8967-8971
9. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Ann. Biochem. 162 (1987) 156-157
10. Chowdrey H.S., Larsen P.J., Harbuz M.S., Lightman S.L., and Jessop D.S. Endogenous substance P inhibits the expression of corticotropin-releasing hormone during a chronic inflammatory stress. Life Sci. 57 (1995) 2021-2029
11. Cibelli G., Corsi P., Diana G., Vitiello F., and Thiel G. Corticotropin-releasing factor triggers neurite outgrowth of a catecholaminergic immortalized neuron via cAMP and MAP kinase signalling pathways. Eur. J. Neurosci. 13 (2001) 1339-1348
12. Coiro V., Capretti L., Volpi R., Davoli C., Marcato A., Cavazzini U., Caffarri G., Rossi G., and Chiodera P. Stimulation of ACTH/cortisol by intravenously infused substance P in normal men: inhibition by sodium valproate. Neuroendocrinology. 56 (1992) 459-463
13. Fiebich B.L., Schleicher S., Butcher R.D., Craig A., and Lieb K. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. J. Immunol. 165 (2000) 5606-5611
14. Gilmor M.L., Skelton K.H., Nemeroff C.B., and Owens M.J. The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. J. Pharmacol. Exp. Ther. 305 (2003) 434-439
15. Grossman A., Costa A., Navarra P., and Tsagarakis S. The regulation of hypothalamic corticotropin-releasing factor release: in vitro studies. Ciba Found. Symp. 172 (1993) 129-143
16. Guo C.J., Lai J.P., Luo H.M., Douglas S.D., and Ho W.Z. Substance P up-regulates macrophage inflammatory protein-1beta expression in human T lymphocytes. J. Neuroimmunol. 131 (2002) 160-167
17. Harrison T., Williams B.J., Swain C.J., and Ball R.G. Piperidine-ether based hNK1 antagonists 1: determination of the relative and absolute stereochemical requirements. Bioorg. Med. Chem. Lett. 4 (1994) 2545-2550
18. Herpfer I., and Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 19 (2005) 275-293
19. Heuillet E., Menager J., Fardin V., Flamand O., Bock M., Garret C., Crespo A., Fallourd A.M., and Doble A. Characterization of a human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG. J. Neurochem. 60 (1993) 868-876
20. Holsboer F. Corticotropin-releasing hormone modulators and depression. Curr. Opin. Investig. Drugs 4 (2003) 46-50
21. Iredale P.A., Bundey R., and Duman R.S. Phorbol ester and calcium regulation of corticotrophin-releasing factor receptor 1 expression in a neuronal cell line. J. Neurochem. 69 (1997) 1912-1919
22. Jessop D.S., Renshaw D., Larsen P.J., Chowdrey H.S., and Harbuz M.S. Substance P is involved in terminating the hypothalamo-pituitary-adrenal axis response to acute stress through centrally located neurokinin-1 receptors. Stress 3 (2000) 209-220
23. Jeurissen F., Kavelaars A., Korstjens M., Broeke D., Franklin R.A., Gelfand E.W., and Heijnen C.J. Monocytes express a non-neurokinin substance P receptor that is functionally coupled to MAP kinase. J. Immunol. 152 (1994) 2987-2994
24. Keller M., Jackisch R., Seregi A., and Hertting G. Comparison of prostanoid forming capacity of neuronal and astroglia cells in primary culture. Neurochem. Int. 7 (1985) 655-665
25. Kiang J.G., Wang X., and McClain D.E. Corticotropin-releasing factor increases protein kinase C activity by elevating membrane-bound alpha and beta isoforms. Chin. J. Physiol. 37 (1994) 105-110
26. Kramer M., Cutler S., Feighner N., Shrivastava J., Carman R., Sramek J., Reines J.J., Liu S.A., Snavely G., Wyatt-Knowles D., Hale E., Mills J.J., MacCoss S.G., Swain M., Harrison C.J., Hill T., Hefti R.G., Scolnick F., Cascieri E.M., Chicchi M.A., Sadowski G.G., Williams S., Hewson A.R., Smith L., and Rupniak D. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281 (1998) 1640-1645
27. Kramer M.S., Winokur A., Kelsey J., Preskorn S.H., Rothschild A.J., Snavely D., Ghosh K., Ball W.A., Reines S.A., Munjack D., Apter J.T., Cunningham L., Kling M., Bari M., Getson A., and Lee Y. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29 (2004) 385-392
28. Lieb K., Fiebich B.L., Berger M., Bauer J., and SchulzeOsthoff K. The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J. Immunol. 159 (1997) 4952-4958
29. Lieb K., Schaller H., Bauer J., Berger M., SchulzeOsthoff K., and Fiebich B.L. Substance P and histamine induce interleukin-6 expression in human astrocytoma cells by a mechanism involving protein kinase C and nuclear factor-IL-6. J. Neurochem. 70 (1998) 1577-1583
30. Lieb K., Ahlvers K., Dancker K., Strohbusch S., Reincke M., Feige B., Berger M., Riemann D., and Voderholzer U. Effects of the neuropeptide substance p on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology 27 (2002) 1041-1049
31. Lieb K., Treffurth Y., Hamke M., Akundi R.S., von Kleinsorgen M., and Fiebich B.L. Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P receptor. J. Neurochem. 86 (2003) 69-76
32. Lieb K., Walden J., Grunze H., Fiebich B.L., Berger M., and Normann C. Serum levels of substance P and response to antidepressant pharmacotherapy. Pharmacopsychiatry 37 (2004) 238-239
33. Luo W., Sharif T.R., and Sharif M. Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res. 56 (1996) 4983-4991
34. Malendowicz L.K., Andreis P.G., Nussdorfer G.G., and Markowska A. The possible role of endogenous substance P in the modulation of the response of rat pituitary-adrenal axis to stresses. Endocr. Res. 22 (1996) 311-318
35. Martin F.C., Charles A.C., Sanderson M.J., and Merrill J.E. Substance P stimulates IL-1 production by astrocytes via intracellular calcium. Brain Res. 599 (1992) 13-18
36. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., and Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226 (1984) 1342-1344
37. Norris J.G., Tang L.P., Sparacio S.M., and Benveniste E.N. Signal transduction pathways mediating astrocyte IL-6 induction by IL-1 beta and tumor necrosis factor-alpha. J. Immunol. 152 (1994) 841-850
38. Nussdorfer G.G., and Malendowicz L.K. Role of tachykinins in the regulation of the hypothalamo-pituitary-adrenal axis. Peptides 19 (1998) 949-968
39. Ogo H., Kuroyanagi N., Inoue A., Nishio H., Hirai Y., Akiyama M., DiMaggio D.A., Krause J.E., and Nakata Y. Human astrocytoma cells (U-87 MG) exhibit a specific substance P binding site with the characteristics of an NK-1 receptor. J. Neurochem. 67 (1996) 1813-1820
40. Otsuka M., and Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73 (1993) 229-308
41. Palma C., and Maggi C.A. The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci. 67 (2000) 985-1001
42. 2 production. Glia 21 (1997) 183-193
43. Pennefather J.N., Lecci A., Candenas M.L., Patak E., Pinto F.M., and Maggi C.A. Tachykinins and tachykinin receptors: a growing family. Life Sci. 74 (2004) 1445-1463
44. Petersenn S., Rasch A.C., Presch S., Beil F.U., and Schulte H.M. Characterization of the human somatostatin receptor type 4 promoter. Mol. Cell Endocrinol. 188 (2002) 75-83
45. Pioro E.P., Mai J.K., and Cuello A.C. Distribution of substance P and enkephalin immunoreactive neurons and fibers. In: Paxinos (Ed). The Human Nervous System (1990), Academic press 1051-1094
46. Pisarchik A., and Slominski A.T. Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression. FASEB J. 15 (2001) 2754-2756
47. Quartara L., and Maggi C.A. The tachykinin NK1 receptor: Part I. ligands and mechanisms of cellular activation. Neuropeptides 31 (1997) 537-563
48. Reisine T. Somatostatin desensitization: loss of the ability of somatostatin to inhibit cyclic AMP accumulation and adrenocorticotropin hormone release. J. Pharmacol. Exp. Ther. 229 (1984) 14-20
49. Rimon R., LeGreves P., Nyberg F., Heikkila L., Salmela L., and Terenius L. Elevation of substance P-like peptides in the CSF of psychiatric patients. Biol. Psychiatry 19 (1984) 509-516
50. Rupniak N.M. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Curr. Opin. Investig. Drugs 3 (2002) 257-261
51. Rupniak N.M., and Kramer M.S. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci. 20 (1999) 485-490
52. Rupniak N.M., Carlson E.J., Webb J.K., Harrison T., Porsolt R.D., Roux S., De Felipe C., Hunt S.P., Oates B., and Wheeldon A. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav. Pharmacol. 12 (2001) 497-508
53. Saban M.R., Nguyen N.B., Hammond T.G., and Saban R. Gene expression profiling of mouse bladder inflammatory responses to LPS, substance P, and antigen-stimulation. Am. J. Pathol. 160 (2002) 2095-2110
54. Sergeyev V., Hokfelt T., and Hurd Y. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. NeuroReport 10 (1999) 3967-3970
55. Severini C., Improta G., Falconieri-Erspamer G., Salvadori S., and Erspamer V. The tachykinin peptide family. Pharmacol. Rev. 54 (2002) 285-322
56. Stout S.C., Owens M.J., and Nemeroff C.B. Neurokinin(1) receptor antagonists as potential antidepressants. Annu. Rev. Pharmacol Toxicol. 41 (2001) 877-906
57. Tan H., Zhong P., and Yan Z. Corticotropin-releasing factor and acute stress prolongs serotonergic regulation of GABA transmission in prefrontal cortical pyramidal neurons. J. Neurosci. 24 (2004) 5000-5008
58. Too H.P., Marriott D.R., and Wilkin G.P. Preprotachykinin-A and substance P receptor (NK1) gene expression in rat astrocytes in vitro. Neurosci. Lett. 182 (1994) 185-187
59. Torrens Y., Beaujouan J.C., Saffroy M., DaguetdeMontety M.C., Bergstrom L., and Glowinski J. Substance P receptors in primary cultures of cortical astrocytes from the mouse. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 9216-9220
60. Torrens Y., Daguet de Montety M.C., el Etr M., Beaujouan J.C., and Glowinski J. Tachykinin receptors of the NK1 type (substance P) coupled positively to phospholipase C on cortical astrocytes from the newborn mouse in primary culture. J. Neurochem. 52 (1989) 1913-1918
61. Torrens Y., Beaujouan J.C., Saffroy M., and Glowinski J. Further evidence for the presence of peptide-sensitive tachykinin binding sites in tissues possessing solely NK(1) tachykinin receptors. Biochem. Biophys. Res. Commun. 270 (2000) 668-672
62. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Ising M., and Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34 (2000) 171-181